** Shares of drug developer HCW Biologics HCWB.O rise 252% to 97 cents
** HCWB says it received U.S. FDA's clearance to start clinical trial for treatment of moderate-to-severe alopecia areata, which is an autoimmune disease that causes sudden hair loss
** HCWB says drug HCW9302 is protein therapy that helps reduce inflammation and promote hair growth
** Co says if trial is successful, HCW9302 may also be used to treat other diseases, including skin conditions, arthritis, and diabetes
** More than 154 mln shares traded, 578x their 25-day moving average
** HCWB shares fell 62.5% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。